Physician profile
David Duane Tanner
NPI 1396785218
$10,391.80
in general payments reported to CMS, 2019-2025
37 companies · $2,080 in 2025
The $2,080 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $991 · 2021: $1,752 · 2022: $1,359 · 2023: $1,052 · 2024: $1,820 · 2025: $2,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,946 · Education: $6.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,945.88 |
| Education | $6.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,271.31 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,254.22 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,058.42 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $843.93 | 2020-2025 | Takhzyro, Cuvitru |
| Csl Behring | $727.27 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Covis Pharma Gmbh | $690.89 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $576.26 | 2021-2025 | Orladeyo |
| Octapharma USA, INC. | $401.35 | 2019-2025 | Cutaquig, Panzyga |
| Pharming Healthcare, INC. | $382.70 | 2019-2025 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $333.32 | 2019-2025 | Dupixent |
| Kaleo, INC. | $325.23 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $282.30 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $264.98 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $228.09 | 2025 | Neffy |
| Amgen INC. | $222.35 | 2022-2025 | Tezspire |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $205.87 | 2019-2025 | |
| Genentech USA, INC. | $205.13 | 2019-2024 | Xolair |
| Grifols USA, LLC | $187.09 | 2023-2025 | Xembify |
| Teva Pharmaceuticals USA, INC. | $165.14 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.06 | 2019-2021 | |
| Lilly USA, LLC | $112.67 | 2023-2025 | Ebglyss, Taltz |
| Alk-Abello, INC | $79.68 | 2019-2022 | |
| Jubilant Hollisterstier LLC | $57.37 | 2021 | |
| Leo Pharma INC. | $50.48 | 2022-2025 | Anzupgo |
| Organon LLC | $45.00 | 2025 | Vtama |
| Kedrion Biopharma, INC. | $43.93 | 2024-2025 | Kedrab, Koate, Gammaked |
| Cycle Pharmaceuticals INC | $43.77 | 2024-2025 | Sajazir |
| Dermavant Sciences, INC. | $25.87 | 2024 | Vtama |
| Greer Laboratories, INC. | $25.48 | 2024 | Oralair |
| Abbvie INC. | $22.26 | 2023 | Rinvoq |
| Adma Biomanufacturing LLC | $21.54 | 2021 | |
| Sunovion Pharmaceuticals INC. | $20.88 | 2019 | |
| Aimmune Therapeutics, INC. | $19.93 | 2022 | |
| Merck Sharp & Dohme LLC | $19.82 | 2023 | |
| Hikma Pharmaceuticals USA | $18.84 | 2023 | Ryaltris |
| Biocryst Pharmaceuticals, INC. | $17.27 | 2020 | |
| Sanofi Pasteur INC. | $17.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.